Financial Daily from THE HINDU group of publications
Saturday, Feb 25, 2006


News
Features
Stocks
Shipping
Archives
Google

Group Sites

Corporate - New Products & Services
Industry & Economy - Pharmaceuticals


Hetero unveils bird flu drug

Our Bureau

Hyderabad , Feb. 24

Hetero Drugs Ltd (HDL), the Hyderabad-based Rs 1,000-crore pharma company with leadership in anti-retrovirals, has unveiled what it called the country's first indigenously produced bird flu drug, Oseltamivir, in 75mg capsules.

Hetero is producing the generic copies of Tamiflu, a patented drug from the Swiss drug maker Roche. The drug is said to be effective in treating the worst symptoms of avian flu in human beings.

This is the first sub-license granted to an Indian pharma company by a multinational drug major under the new patents regime, according to the HDL Chairman and Managing Director, Dr B. Parthasarathy Reddy.

Hetero's launch of bird flu drug comes close on the heels of the country reporting its first outbreak of bird flu last week. However, the health officials are still awaiting test reports to see if the deadly virus infected any humans, he said.

Suspecting that people would panic and start taking the pills irrespective of whether they were infected with the virus, the Government did not permit retail sales of the generic bird flu drug. The Government fears that with such indiscriminate use of the generic drug regardless of whether or not infected by the virus, the disease could develop resistance.

Hetero Drugs, which had already supplied 5-lakh pills to the Government for combating the pandemic, has delivered another consignment of 2-lakh capsules on Wednesday.

Speaking at the launch of the drug, Dr Reddy said under the arrangement with Roche, Hetero Drugs would produce the generic drug and supply to the domestic market and also export to around 100 under-developed and developing countries across the globe.

More Stories on : New Products & Services | Pharmaceuticals | Poultry | Health

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page



Stories in this Section
JSW Steel hikes price


Glenmark trials on diabetes drug
Dutch firm refutes vaccine charges
Ministry yet to settle GAIL, ONGC row
Birlas want probe by Telecom Dept
Madhucon Projects allots GDRs
Electrosteel Castings FCCB issue likely in April
ONGC told not to award deal
Kerala: Audit by CAs in co-op banks, societies urged
Amtek Auto to bring 2 group cos under fold
Videocon to bid for Daewoo Elect
Rain Calcining floats SPV for routing overseas investments
Stone for footwear plant to be laid today
Gateway Distriparks to invest Rs 200 cr for new facilities
US co opens innovation Chennai centre
PSL commissions Vizag plant
Areva T&D to invest euro 50 m in power sector
POSCO India MD appointed to board
USFDA nod for Aurobindo's Lisinopril
AIMA interactive meet
ITC unit to apply for carbon credits
Water, oil to drive Krohne Marshall growth
Jessop on expansion drive
Hetero unveils bird flu drug
New Mercedes models unveiled
DaimlerChrysler to roll out Actros trucks, luxury buses




The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright © 2006, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line